Bobby Liaw

Genitourinary Oncology, Icahn School of Medicine at Mount Sinai

[Blue Cure @BlueCure]

. @BobbyLiawMD: What Young Guys Should Do Now to Prevent #ProstateCancer Later
https://t.co/819xkXTfI0

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

If you had #COVID19 and have recovered you can help save a life. Your blood may contain antibodies that fight the virus and can help critically ill people. Mount Sinai is looking to screen you as a volunteer. Fill out this form to see if you are eligible: https://t.co/stBkMdIiaR

[Reza Mehrazin, MD @MehrazinMD]

Great summary of adjuvant trials in #kidneycancer @kai_tsao @OncLiveSOSS

[Dr. John Sfakianos @DrJohnSfakianos]

Learning a ton from @kai_tsao @TischCancer about adjuvant treatment in #RCC @OncLiveSOSS

[Reza Mehrazin, MD @MehrazinMD]

@MattGalsky kicking off @OncLiveSOSS ‘s event on Genitourinary Cancers #StateofScience @MountSinaiNYC @TischCancer

[Kai Tsao @kai_tsao]

Our own Dr John Sfakianos giving a talk on non-muscle invasive bladder cancer at the OncLive state of the science summit @DrJohnSfakianos @TischCancer @IcahnMountSinai @MountSinaiNYC

[William K. Oh MD @WilliamOhMD]

@MattGalsky discussing adjuvant therapy in bladder cancer. #GU20 @TischCancer @IcahnMountSinai

[Kai Tsao @kai_tsao]

What happens to patients with advanced GU cancers treated with immune checkpoint inhibitors at radiographic disease progression?
@VaibhavPatelMD @anishbparikh @WilliamOhMD @MattGalsky @kai_tsao @TischCancer @IcahnMountSinai @JanieQian

[Kai Tsao @kai_tsao]

Who get immune mediated adverse events on CPI therapy? @JanieQian @VaibhavPatelMD @anishbparikh @WilliamOhMD @MattGalsky @kai_tsao @TischCancer @IcahnMountSinai

[Bobby Liaw @BobbyLiawMD]

Thanks to @SBOC_Oncologia for inviting us to speak!

[Reza Mehrazin, MD @MehrazinMD]

A great and comprehensive review of agents for treatment of hormone sensitive #prostatecancer by @BobbyLiawMD @TischCancer

[Bobby Liaw @BobbyLiawMD]

Really thoughtful discussion by @MehrazinMD on the challenges of robotic retroperitoneal approach for #kidneycancer.
@MountsinaiUro @TischCancer @SBOC_Oncologia

[Bobby Liaw @BobbyLiawMD]

Character limits are the worst! Agonizing over which 7 characters won't make the cut for abstract submission

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

Cutting-edge #ProstateCancer drugs that help extend life in the toughest cases might also be useful in fighting less aggressive #tumors, two new #clinical trials suggest. Dr. Bobby Liaw, who was not involved in the trials, weighs in: https://t.co/nH7AbV25bm #MensHealthMonth

[William K. Oh MD @WilliamOhMD]

Our review on "The evolving landscape of immunotherapy in advanced prostate cancer" Great job by @vaibhavpatelmd @tischcancer @mountsinainyc | Immunotherapy https://t.co/OjAYvEeucc

[Toni Choueiri, MD @DrChoueiri]

Very strong data of Enfortumab Vedotin in this phase II trial in a setting of great unmet need: post-chemo and ICI!
ORR of 44% and CR of 12% and being submitted for accelerated approval.
Potentially practice-changing...
#ASCO19 @ASCO

[Bobby Liaw @BobbyLiawMD]

@MattGalsky presents on HCRN GU14-182, switch maintenance with pembrolizumab after completion of first line platinum-based chemotherapy associated with improved PFS, deeper responses. #ASCO19 @TischCancer @MountSinaiNYC

[Bobby Liaw @BobbyLiawMD]

@WilliamOhMD Can we improve therapeutic response to enzalutamide? Should be an easier task than getting PowerPoint to consistently work... #ASCO19

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

Attention Day 2 #ASCO19 Attendees: Join Dr. William K. Oh, Deputy Director of @TischCancer, as he shares his oral abstract on "ENZA-mining: #Resistance and Combination #Therapy," today, June 1 at 4:30pm CDT in Arie Crown Theater. #ASCO19

[Mount Sinai Tisch Cancer Center @TischCancer]

We are proud to have our cutting-edge research, clinical care and education be represented at @ASCO in #Chicago! Visit us at Booth 4025 to learn about our services! #ASCO19 #Oncology

[William K. Oh MD @WilliamOhMD]

We are excited to grow our presence at #ASC019